Eiko emphasizes the importance of qualitative experiences in understanding treatment outcomes, particularly in antidepressant and psychotherapy research. He critiques the study's design, noting that participants in the MDMA group are likely aware of their treatment, while those receiving placebo also recognize their status, which complicates the validity of the results. The higher dropout rate in the control group raises further concerns about the study's methodological soundness.
